Pharmaceutical company Chimerix reached an agreement with the U.S. Food and Drug Administration Tuesday to provide a 7-year-old boy with an experimental drug that could save his life.
The company initially refused to provide Josh Hardy with brincidofovir, which is still in the trial phase, because it said it had hundreds of such requests, which slowed down its efforts to study its effectiveness to treat adenovirus.